Hey, thanks for putting this together! A few high level questions my group and I had regarding the challenge?
- What will happen downstream of platform for classifying active antibodies? Have the 48 antibodies in the training set been tested in a clinical setting? We're curious how making a model for the open task will be used for discovery. - How is the data for the open task of antibodies against bacterial infection specific to covid-19? Is there something that makes the 'secondary infection problem' easier, or a subset of the general problem of identifying antibiotics that treat drug-resistant bacteria? - Is it known how many people die because of secondary infection, as opposed to just with it? From my understanding of the literature it seems many who don't survive do indeed have secondary infection; however how often is it the cause among cytokine storm/inflammatory response/etc?